Infant Bacterial Therapeutics AB (STU:9IB) ROCE % : -71.64% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Infant Bacterial Therapeutics AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -71.64%.

Infant Bacterial Therapeutics AB ROCE % Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB ROCE % Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-15.33

-10.62

-17.27

-38.30

-56.57

Infant Bacterial Therapeutics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-51.74	-37.97	-66.50	-59.09	-71.64

Infant Bacterial Therapeutics AB ROCE % Calculation

Infant Bacterial Therapeutics AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-11.902	/	( ( (31.408 - 4.128)	+	(20.827 - 6.025) )	/ 2 )
	=	-11.902	/	( (27.28	+	14.802)	/ 2 )
	=	-11.902	/	21.041
	=	-56.57 %

Infant Bacterial Therapeutics AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-11.74	/	( ( (21.079 - 3.107)	+	(20.827 - 6.025) )	/ 2 )
	=	-11.74	/	( ( 17.972	+	14.802 )	/ 2 )
	=	-11.74	/	16.387
	=	-71.64 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Infant Bacterial Therapeutics AB (STU:9IB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Infant Bacterial Therapeutics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines